Literature DB >> 26614360

Target selected treatment with levamisole to control the development of anthelmintic resistance in a sheep flock.

Ana Carolina de Souza Chagas1, Luciana Ferreira Domingues2, Yousmel Alemán Gaínza3, Waldomiro Barioni-Júnior2, Sérgio Novita Esteves2, Simone Cristina Méo Niciura2.   

Abstract

Levamisole phosphate, chosen based on its 100 % efficacy demonstrated by a previous fecal egg count reduction test (FECRT), was used as the exclusive anthelmintic treatment in the Embrapa Southeast Livestock sheep flock from 2009 to 2014 in a target selected treatment scheme. In the present study, the effectiveness of this nematode control scheme was evaluated after 5 years by FECRT, larval development test (LDT), and a molecular test to assess the development of levamisole resistance in Haemonchus contortus. Animals were submitted to treatments with albendazole, levamisole, closantel, ivermectin, moxidectin, and monepantel. Eggs per gram of feces (EPG) counts and fecal cultures were performed, and anthelmintic efficacy was calculated by the RESO 4.0 program. The helminths of the flock (GIN Embrapa2014) were compared to susceptible (McMaster) and resistant (Embrapa2010) H. contortus isolates in the LDT to estimate the LC50 and LC90 of levamisole and in a molecular test to evaluate the 63-bp indel in the acr8 gene associated with levamisole resistance. In the FECRT, parasites were susceptible to monepantel (99.6 %) and closantel (98.3 %), but resistant to moxidectin (93.8 %), levamisole (70.4 %), ivermectin (48.1 %), and albendazole (0 %). In the coproculture on D14, and the control group presented 80 % H. contortus and 20 % Trichostrongylus sp., while in the monepantel group L1 were observed as well as Oesophagostomum sp. L3. LDT and resistance factors provided good separation between susceptible and resistant parasites. The genotypic frequencies of the 63-bp insertion in the acr8 gene in H. contortus were 11.9, 6.7, and 0 % in GIN Embrapa2014, Embrapa2010, and McMaster isolates, respectively. After 5 years of exclusive use, the nematodes developed resistance to levamisole, detected by FECRT and by increase in LC50 and LC90 for levamisole in the LDT. The 63-bp indel was not confirmed as a molecular marker of levamisole resistance in our isolates. The target selected treatment scheme was effective to control helminths in the sheep flock for 5 years, when levamisole's inefficacy was perceived because of no change in the clinical situation of treated animals. Through this scheme, it was possible to promote reversion towards susceptibility or increase of efficacy for other chemical classes. Thus, this is a valid recommendation to control worms and to delay the development of resistance, preserving other anthelmintic classes for future use.

Entities:  

Keywords:  FECRT; Genetic marker; Haemonchus contortus isolates; Levamisole resistance; Reversion; acr8 gene

Mesh:

Substances:

Year:  2015        PMID: 26614360     DOI: 10.1007/s00436-015-4844-x

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  40 in total

1.  The sexually linked Mpi locus is presumably involved in imidothiazole resistance in Oesophagostomum dentatum parasites.

Authors:  V Snábel; T DeMeeŵs; M Várady; P Nansen; H Bjørn; J Corba
Journal:  Parasitol Res       Date:  2000-06       Impact factor: 2.289

2.  Anthelmintic resistance in New Zealand.

Authors:  D M Leathwick; W E Pomroy; A C Heath
Journal:  N Z Vet J       Date:  2001-12       Impact factor: 1.628

Review 3.  Anthelmintic resistance of gastrointestinal parasites in small ruminants.

Authors:  Sherrill A Fleming; Tom Craig; Ray M Kaplan; James E Miller; Christine Navarre; Mike Rings
Journal:  J Vet Intern Med       Date:  2006 Mar-Apr       Impact factor: 3.333

4.  Drug resistance mechanisms in helminths: is it survival of the fittest?

Authors:  Catherine E James; Amanda L Hudson; Mary W Davey
Journal:  Trends Parasitol       Date:  2009-06-21

5.  Detecting benzimidazole resistance with faecal egg count reduction tests and in vitro assays.

Authors:  P J Martin; N Anderson; R G Jarrett
Journal:  Aust Vet J       Date:  1989-08       Impact factor: 1.281

6.  cDNA-AFLP analysis in levamisole-resistant Haemonchus contortus reveals alternative splicing in a nicotinic acetylcholine receptor subunit.

Authors:  Aymeric Fauvin; Claude Charvet; Mohamed Issouf; Jacques Cortet; Jacques Cabaret; Cédric Neveu
Journal:  Mol Biochem Parasitol       Date:  2009-11-22       Impact factor: 1.759

7.  The efficacy of monepantel, an amino-acetonitrile derivative, against gastrointestinal nematodes of sheep in three countries of southern Latin America.

Authors:  Miguel Bustamante; Pedro E Steffan; Jorge Bonino Morlán; Flavio Echevarria; César A Fiel; Herculano Cardozo; Daniel Castells; Barry C Hosking
Journal:  Parasitol Res       Date:  2009-09-30       Impact factor: 2.289

8.  A telephone survey of internal parasite control practices on sheep farms in Spain.

Authors:  Francisco A Rojo-Vázquez; Barry C Hosking
Journal:  Vet Parasitol       Date:  2012-11-12       Impact factor: 2.738

9.  F200Y polymorphism in the β-tubulin gene in field isolates of Haemonchus contortus and risk factors of sheep flock management practices related to anthelmintic resistance.

Authors:  Simone Cristina Méo Niciura; Cecília José Veríssimo; Juliana Gracielle Gonzaga Gromboni; Marina Ibelli Pereira Rocha; Suelen Scarpa de Mello; Cristina Maria Pacheco Barbosa; Daniela Pontes Chiebao; Daniel Cardoso; Giane Serafim Silva; Ivani Pozar Otsuk; José Roberto Pereira; Luis Alberto Ambrosio; Romeu Fernandes Nardon; Tatiana Evelyn Hayama Ueno; Marcelo Beltrão Molento
Journal:  Vet Parasitol       Date:  2012-07-20       Impact factor: 2.738

10.  Drug-efflux and target-site gene expression patterns in Haemonchus contortus larvae able to survive increasing concentrations of levamisole in vitro.

Authors:  Ranbir S Sarai; Steven R Kopp; Glen T Coleman; Andrew C Kotze
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-03-13       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.